This company has been marked as potentially delisted and may not be actively trading. Medicenna Therapeutics (MDNA) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock MDNA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational HighlightsAugust 1, 2025 | globenewswire.comMedicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | globenewswire.comMedicenna Therapeutics With Founder, Chairman, President & CEO, Dr. Fahar MerchantMay 14, 2025 | msn.comMedicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 22, 2025 | markets.businessinsider.comMedicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)February 23, 2025 | theglobeandmail.comMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025February 5, 2025 | globenewswire.comThese TSX stocks saw more gains in 2024 than all the others, so farDecember 27, 2024 | msn.comMedicenna’s MDNA11 Shows Promise in Cancer TreatmentDecember 13, 2024 | tipranks.comMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 13, 2024 | globenewswire.comMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 StudyDecember 5, 2024 | globenewswire.comUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge ConferenceNovember 27, 2024 | financialpost.comFMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)November 25, 2024 | finance.yahoo.comMedicenna Showcases Promising Results and Strong FinancialsNovember 16, 2024 | markets.businessinsider.comMedicenna to Present Innovative Cancer Data at ConferencesNovember 13, 2024 | markets.businessinsider.comMedicenna announces single-agent activity of MDNA11 from dose expansion cohortNovember 11, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Buy Rating for Medicenna Therapeutics’ MDNA11November 11, 2024 | markets.businessinsider.comMedicenna Announces Breakthroughs in Cancer TreatmentNovember 9, 2024 | markets.businessinsider.comMedicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 4, 2024 | markets.businessinsider.com3 TSX Growth Stocks To Watch With Up To 39% Insider OwnershipSeptember 24, 2024 | finance.yahoo.comMedicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy ConferenceAugust 27, 2024 | finance.yahoo.com3 Growth Stocks On The TSX With Insider Ownership Up To 21%August 16, 2024 | finance.yahoo.comHutchison's Three UK says operating loss shows need for Vodafone mergerAugust 15, 2024 | msn.comMedicenna Strengthens Board of Directors with Appointment of Karim LaljiAugust 15, 2024 | markets.businessinsider.com3 TSX Growth Companies With High Insider Ownership Expecting Up To 71% Earnings GrowthAugust 14, 2024 | finance.yahoo.com3 High Growth Companies With Strong Insider Ownership On TSXAugust 12, 2024 | finance.yahoo.comClosing Bell: Medicenna Therapeutics Corp flat on Tuesday (MDNA)July 24, 2024 | theglobeandmail.comMedicenna Therapeutics Corp. (MDNA.TO)May 26, 2024 | finance.yahoo.comMDNA:CA Medicenna Therapeutics Corp.May 12, 2024 | seekingalpha.comMedicenna Therapeutics Corp (MDNA)May 10, 2024 | investing.comMedicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital ManagementApril 30, 2024 | finance.yahoo.comMedicenna Therapeutics Corp.: Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual MeetingApril 24, 2024 | finanznachrichten.deMedicenna reports advancement in cancer immunotherapyApril 11, 2024 | investing.comMedicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 4, 2024 | finance.yahoo.comMedicenna Therapeutics Corp MDNAMarch 1, 2024 | morningstar.comMMedicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateFebruary 14, 2024 | finance.yahoo.comMedicenna Announces Appointment of New AuditorJanuary 12, 2024 | tmcnet.comMedicenna Announces Trading on the OTCQB Under the Symbol MDNAFDecember 19, 2023 | finance.yahoo.comMDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…November 20, 2023 | finance.yahoo.comMedicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 14, 2023 | finance.yahoo.comMDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11November 13, 2023 | finance.yahoo.comMedicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)November 6, 2023 | finance.yahoo.comMedicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)November 3, 2023 | finance.yahoo.comWhy Is Medicenna Therapeutics (MDNA) Stock Down Today?October 30, 2023 | msn.comMedicenna Announces Nasdaq Delisting and Cutback of Management TeamOctober 27, 2023 | finance.yahoo.comMedicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsOctober 25, 2023 | finance.yahoo.comClosing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)October 13, 2023 | theglobeandmail.comMedicenna Therapeutics Names Humphrey Gardner CMOOctober 10, 2023 | markets.businessinsider.comMedicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 10, 2023 | finance.yahoo.comMedicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 28, 2023 | finance.yahoo.comMedicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94September 13, 2023 | nasdaq.com Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDNA Media Mentions By Week MDNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDNA News Sentiment▼0.001.09▲Average Medical News Sentiment MDNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDNA Articles This Week▼00▲MDNA Articles Average Week Get the Latest News and Ratings for MDNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Medicenna Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AADI News EGRX News PYRGF News NNVC News IBIO News MTNB News AEON News NRBO News NBY News OGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDNA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDNA Stock Alerts